TICKERNERD
Menu
PCRXPCRXHealthcare · Drug Manufacturers - Specialty & Generic

PCRX Stock Forecast: Pacira Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$25
+3.52% on the day

The 7 Wall Street analysts covering Pacira Biosciences, Inc. hold a median 12-month price target of $30 — +21.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 21 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$949.9M
Ticker Nerd rank
99 / 100
Median analyst target
$30
Analysts covering
7
Total return, dividends reinvested
1W
+7.3%
1M
−4.3%
YTD
−4.7%
1Y
−2.8%
From 52W high
−10.7%
From 52W low
+28.8%
$19
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pacira Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
100
Value
100
Accruals
99
Quality
95
Volatility
92
Growth
78
Momentum
63
Revisions
52
Size
45

Issuance (100): The share count has been shrinking and the company is not leaning on new borrowing.

Revisions (52): Analysts have, on balance, been cutting their forecasts.

Size (45): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PCRXHigh $38Median $30Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
4 Buy2 Hold1 Sell
Low $23Median $30High $38

The green dot is the last close — the median target sits +21.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026NeedhamMaintainsBuy$32 → $33
5 Aug 2026RBC CapitalMaintainsSector Perform$24 → $25
1 July 2026HC Wainwright & Co.ReiteratesBuy$38
1 July 2026HC Wainwright & Co.ReiteratesBuy—
1 May 2026NeedhamMaintainsBuy—
1 May 2026RBC CapitalMaintainsSector Perform—
26 Mar 2026BarclaysMaintainsEqual-Weight—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026NeedhamMaintainsBuy—
9 Dec 2025BarclaysInitiatesEqual-Weight—
17 Nov 2025HC Wainwright & Co.AssumesBuy$38
7 Nov 2025Truist SecuritiesMaintainsBuy—
9 May 2025NeedhamMaintainsBuy—
8 Apr 2025HC Wainwright & Co.MaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—
28 Feb 2025BarclaysMaintainsOverweight—
28 Feb 2025HC Wainwright & Co.MaintainsBuy—
28 Feb 2025NeedhamMaintainsBuy—
30 Jan 2025Truist SecuritiesUpgradeHold—
14 Jan 2025RBC CapitalReiteratesSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PCRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.7%
Analysts raising
2
Analysts cutting
1
Fundamentals

Pacira Biosciences, Inc. (PCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
69.5×

Cheaper than 10% of US stocks

Price / sales
1.3×

Cheaper than 64% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
9.0×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
6.2%

Higher than 42% of US stocks

Earnings growth (YoY)
6.2%

Higher than 43% of US stocks

Gross margin
77.0%

Higher than 89% of US stocks

Operating margin
6.2%

Higher than 57% of US stocks

Net margin
2.0%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.5%

Higher than 55% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PCRXPacira Biosciences, Inc.$949.9M
99
AMPHAmphastar Pharmaceuticals, Inc.$952.4M
85
COLLCollegium Pharmaceutical, Inc.$857.0M
80
GLASGlass House Brands, Inc.$810.6M
45
IRWDIronwood Pharmaceuticals, Inc.$699.5M
100
PAHCPhibro Animal Health Corp.$1.5B
89
TLRYTilray Brands, Inc.$659.2M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pacira Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PCRX news & analysis

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Pacira BioSciences granted inducement awards to five new employees on August 4, 2026 under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee without stockholder approval in line with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The grants signal Pacira is hiring and using stock-based incentives to attract new talent, which may be of interest to shareholders tracking company growth and compensation practices.

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

GlobeNewsWire · 6 Aug 2026positive

Pacira BioSciences announced the publication of positive two-year Phase 1 data for PCRX-201 in the Annals of the Rheumatic Diseases. The data showed that a single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis.

Why it matters — A PCRX watcher would care because this publication provides longer-term Phase 1 safety data on PCRX-201, a key candidate in the company's pipeline for treating knee osteoarthritis.

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

Zacks Investment Research · 5 Aug 2026neutral

Pacira (PCRX) beat Q2 earnings estimates, with higher product sales boosting revenues as Exparel demand and portfolio momentum supported growth. However, the company cut its 2026 sales outlook.

Why it matters — A PCRX watcher would care because the earnings beat is a positive signal, but the reduced 2026 sales outlook highlights caution about the company's forward growth prospects.

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the Pacira BioSciences, Inc. (PCRX) Q2 2026 earnings call transcript. The document covers the company's earnings call discussion for the second quarter of 2026.

Why it matters — PCRX watchers can read the full management commentary from the company's Q2 2026 earnings call to gain insight into its quarterly results and outlook.

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Zacks Investment Research · 4 Aug 2026positive

Pacira reported Q2 earnings of $0.73 per share, surpassing the Zacks Consensus Estimate of $0.64 per share. This compares with earnings of $0.74 per share in the same quarter a year ago.

Why it matters — PCRX watchers would care because the company topped consensus earnings expectations, giving a performance read on the quarter relative to analyst forecasts.

FAQ

Frequently asked questions about PCRX stock

What is the PCRX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pacira Biosciences, Inc. have a median 12-month price target of $30, with estimates ranging from $23 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCRX stock a buy right now?

Of the 7 analysts covering Pacira Biosciences, Inc., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacira Biosciences, Inc. 99 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCRX?

As at 21 Aug 2026, Pacira Biosciences, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (100 of 100).

Will PCRX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +21.6% from the last close, and Ticker Nerd's factor model ranks Pacira Biosciences, Inc. 99 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCRX stock forecast for 2030?

No analyst covering Pacira Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $38 over the next 12 months.

How has PCRX stock performed over the past year?

Pacira Biosciences, Inc. returned -2.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pacira Biosciences, Inc. do?

Pacira BioSciences Inc. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative non-opioid pain management therapies.

What is the latest news on PCRX?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Pacira BioSciences granted inducement awards to five new employees on August 4, 2026 under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee without stockholder approval in line with Nasdaq Listing Rule 5635(c)(4).

Company

About Pacira Biosciences, Inc.

Pacira BioSciences Inc. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative non-opioid pain management therapies. Its primary focus is transforming patient care by providing opioid-sparing alternatives for acute, postsurgical, chronic, and musculoskeletal pain, including commercial products like EXPAREL (bupivacaine liposome injectable suspension) for long-acting local analgesia and iovera, which delivers precise cryoneurolysis to targeted nerves. The company advances solutions across the neural pain pathway, from pre-surgical preparation to rehabilitation, emphasizing enhanced recovery protocols that minimize opioid reliance. Pacira BioSciences Inc. also pursues pipeline innovations such as PCRX-201, a gene therapy candidate designed for local injection to boost IL-1Ra production and reduce chronic inflammation in osteoarthritis of the knee. Serving hospitals, ambulatory surgery centers, healthcare practitioners, and patients, the company prioritizes patient safety, rigorous quality controls, and ethical standards in research, manufacturing, and marketing. Headquartered in Tampa, Florida, Pacira BioSciences Inc. leads the shift toward non-opioid standards in pain management.

CEO Mr. Frank D. Lee · 825 employees · United States · https://www.pacira.com